Hemostemix Increases Previously Closed Private Placement to $3,000,000

Core Viewpoint - Hemostemix Inc. has increased the size of its previously closed non-brokered private placement from $2,969,600 to $3,000,000, following additional subscriptions received after the original closing date [1][2]. Group 1: Offering Details - The Offering now includes a total of 3,000,000 additional units at a price of $0.10 per unit [2]. - Each unit consists of one common share and one common share purchase warrant, with the warrant allowing the holder to acquire an additional common share at an exercise price of $0.15 for 24 months [3]. - An acceleration clause is included, allowing the Company to expedite the expiry of the warrants if the common shares' closing price exceeds a weighted average of $0.185 for 10 consecutive trading days [3]. Group 2: Financial Aspects - The Company paid cash finder's fees totaling $100,032 and issued 1,000,320 finder's options, each allowing the purchase of one common share at an exercise price of $0.15 for 24 months [4]. - Proceeds from the Offering will be used to repay CD1 at a 50% discount to face value ($1,250,000) and for general working capital to support ongoing operational expenses, including marketing and sales of VesCell™ [5]. Group 3: Related Party Transactions - The Offering is classified as a "related party transaction" under Multilateral Instrument 61-101, with directors Mr. Peter Lacey and Mr. Loran Swanberg participating directly and indirectly [6]. - The Company will file a material change report regarding the related party transaction on SEDAR+ [6]. - The transaction was approved by the board of directors, including disinterested directors, and no special committee was established [6]. Group 4: Shareholder Impact - Prior to the Offering, Mr. Lacey owned 9,316,937 common shares, representing 6.14% of the total shares [9]. - After subscribing to 15,000,000 units, Mr. Lacey's ownership increased to 24,316,937 common shares, representing 13.40% of the total shares on a non-diluted basis [9].